Lightbeam Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health management and care coordination platform helping health systems and payers close care gaps and manage high-risk patients. Dallas TX.
About
Lightbeam Health is a population health management company that helps healthcare organizations identify, stratify, and engage high-risk patients to improve outcomes and reduce costs in value-based care arrangements. Headquartered in Dallas, Texas, Lightbeam serves health systems, ACOs, and health plans with a platform that aggregates clinical and claims data, applies predictive risk models, and delivers actionable patient lists to care management teams. The company has a strong presence in the ambulatory care market and among organizations pursuing Medicare Shared Savings Program and Medicare Advantage contracts.\n\nLightbeam's platform includes a comprehensive care management workflow tool that allows care coordinators to document interventions, manage care plans, and track outcomes across attributed patient populations. The system integrates with major EHR platforms to deliver real-time clinical context alongside population-level analytics, enabling care managers to move from insight to action without leaving their primary workflow environment. Lightbeam also supports quality measure tracking for HEDIS, CMS Stars, and commercial quality programs, giving organizations a single platform for both care management operations and performance reporting.\n\nThe company has grown through a combination of organic expansion and strategic partnerships with health IT ecosystem players. Lightbeam competes with vendors like Arcadia, Innovaccer, and Zeomega in the population health space, differentiating on depth of care management functionality and configurability for diverse organizational structures including large physician groups and independent practice associations.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.